DDInter1274 DDInter1376
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nefazodone {u} (Compound) resembles {v} (Compound) Hydroxyzine
Nefazodone {u} (Compound) resembles {v} (Compound) Trifluoperazine
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
Nefazodone {u} (Compound) upregulates {v} (Gene) SERPINA3
Nefazodone {u} (Compound) palliates {v} (Disease) endogenous depression
Nefazodone {u} (Compound) downregulates {v} (Gene) ADI1
Nefazodone {u} (Compound) causes {v} (Side Effect) Laryngitis
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Nefazodone (Compound) resembles Hydroxyzine (Compound)
Nefazodone (Compound) resembles Trifluoperazine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Nefazodone (Compound) binds CYP3A4 (Gene)
Nefazodone (Compound) upregulates SERPINA3 (Gene)
Nefazodone (Compound) palliates endogenous depression (Disease)
Nefazodone (Compound) downregulates ADI1 (Gene)
Nefazodone (Compound) causes Laryngitis (Side Effect)
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Bexarotene